Skip to main content

Pacemaker Indication

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Biotronik
BiotronikGermany - Berlin
2 programs
EVIA PacemakerN/A1 trial
VpS algorithm in EVIA and ENTOVIS pacemakersN/A1 trial
Active Trials
NCT00916344Completed175Est. Mar 2010
NCT01053832Completed84Est. Sep 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiotronikVpS algorithm in EVIA and ENTOVIS pacemakers
BiotronikEVIA Pacemaker

Clinical Trials (2)

Total enrollment: 259 patients across 2 trials

NCT01053832BiotronikVpS algorithm in EVIA and ENTOVIS pacemakers

Ventricular Pace Suppression Study

Start: Jan 2010Est. completion: Sep 201184 patients
N/ACompleted
NCT00916344BiotronikEVIA Pacemaker

Master Study for the Investigation of Safety and Efficacy of the EVIA Pacemaker

Start: Jun 2009Est. completion: Mar 2010175 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.